SCHEMBL4151043

SCHEMBL4151043

COc1ccc(Br)cc1C1=C(c2cnnc(C(=O)NC(C)(C)C)c2)CCC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGER1 P34995 9/20 0.43
SMN1; SMN2 Q16637 3/20 0.37
LMNA P02545 2/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
MAPK1 P28482 1/20 0.36
MGAM O43451 1/20 0.35
GAA P10253 1/20 0.35
SI P14410 1/20 0.35
MGAM2 Q2M2H8 1/20 0.35
LRRK2 Q5S007 1/20 0.35
ALDH1A1 P00352 2/20 0.34
MAPT P10636 2/20 0.34
NPSR1 Q6W5P4 2/20 0.34
CYP2C9 P11712 2/20 0.34
CYP1A2 P05177 1/20 0.34
CYP3A4 P08684 1/20 0.34
ALOX12 P18054 1/20 0.34
CYP2C19 P33261 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4155974 0.87 PTGER1 (0.37) PTGER1MEN1KMT2AGAARAB9A
SCHEMBL13697512 0.86 PTGER1 (0.42) PTGER1SMN1; SMN2LMNAMEN1KMT2A
SCHEMBL4149563 0.79 PTGER1 (0.34) PTGER1
SCHEMBL13697505 0.77 PTGER1 (0.58) PTGER1MEN1KMT2ACYP2C9CYP3A4
SCHEMBL4154339 0.75 PTGER1 (0.79) PTGER1CYP2C9
SCHEMBL4158391 0.72 PTGER1 (0.79) PTGER1CYP2C9
SCHEMBL4165937 0.69 PTGER1 (0.58) PTGER1CYP2C9CYP3A4CYP2C19
SCHEMBL4153975 0.69 PTGER1 (0.61) PTGER1CYP2C9CYP3A4CYP2C19
SCHEMBL4149754 0.69 PTGER1 (0.58) PTGER1CYP2C9CYP3A4CYP2C19
SCHEMBL5619860 0.69 PTGER1 (0.47) PTGER1SMN1; SMN2GAACYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090227591-A1 Cyclopentene compounds GLAXO GROUP LIMITED (GB) 2009-09-10 US disclosed
US-20090227591-A1 Cyclopentene compounds GLAXO GROUP LIMITED (GB) 2009-09-10 US disclosed
US-20090227591-A1 Cyclopentene compounds GLAXO GROUP LIMITED (GB) 2009-09-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090227591-A1 Cyclopentene compounds C1R, CYP1B1, ADORA2B PTGER1 246/4885SMN1; SMN2 3323/4885LMNA 1174/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.